Understanding Prediabetes: A Critical Window for Intervention

Prediabetes represents a metabolic state in which blood glucose levels are elevated above normal but remain below the diagnostic thresholds for type 2 diabetes. This condition is far more than a transient laboratory abnormality; it constitutes a high-risk clinical state that significantly increases the likelihood of progression to overt diabetes, cardiovascular disease, chronic kidney disease, and other serious complications. According to the Centers for Disease Control and Prevention, more than 96 million American adults—approximately one in three—meet the laboratory criteria for prediabetes, yet the vast majority remain undiagnosed and unaware of their elevated risk. Without targeted intervention, up to 10 percent of individuals with prediabetes will transition to type 2 diabetes each year.

Lifestyle modification remains the cornerstone of prediabetes management. The landmark Diabetes Prevention Program demonstrated that achieving a 7 percent reduction in body weight combined with at least 150 minutes of moderate-intensity physical activity per week reduced the risk of progressing to diabetes by 58 percent. However, sustaining these behavioral changes over the long term is challenging for many patients, and a substantial proportion fail to meet or maintain these targets. Consequently, pharmacotherapy is increasingly considered as a complementary strategy, particularly for those with high-risk features such as obesity, severe insulin resistance, or metabolic syndrome. Among the emerging pharmacologic options, Rybelsus (oral semaglutide) has drawn considerable attention due to its potent effects on glycemic control, body weight reduction, and cardiometabolic risk factors.

What Is Rybelsus?

Rybelsus is an oral glucagon-like peptide-1 receptor agonist that contains the active ingredient semaglutide, a synthetic analogue of the natural incretin hormone GLP-1. Unlike earlier GLP-1 receptor agonists such as exenatide or liraglutide, which require subcutaneous injection, Rybelsus is formulated as a once-daily tablet. This oral formulation represents a meaningful advance in patient convenience and has the potential to improve medication adherence. The U.S. Food and Drug Administration approved Rybelsus in 2019 as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes.

The oral bioavailability of semaglutide is made possible by the co-formulation with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, a proprietary absorption enhancer that facilitates the drug's passage across the gastric mucosa. Patients must take Rybelsus on an empty stomach, at least 30 minutes before the first meal, beverage, or any other oral medications, to ensure adequate absorption. The available dosages are 3 mg, 7 mg, and 14 mg daily, with a gradual dose-escalation schedule designed to minimize gastrointestinal side effects. The 3 mg dose is used exclusively for treatment initiation and is not considered therapeutic; patients typically advance to 7 mg after 30 days and may subsequently increase to 14 mg based on glycemic response and tolerability.

Mechanism of Action: Targeting the Core Defects of Prediabetes

GLP-1 receptor agonists such as semaglutide mimic the actions of the endogenous incretin hormone glucagon-like peptide-1, which is secreted from intestinal L-cells in response to nutrient ingestion. The physiologic effects of GLP-1 are directly relevant to the pathophysiology of prediabetes and include several complementary actions:

  • Glucose-dependent insulin secretion: Semaglutide stimulates insulin release from pancreatic beta cells only when blood glucose concentrations are elevated. This glucose-dependent mechanism significantly reduces the risk of hypoglycemia, a safety advantage over insulin secretagogues such as sulfonylureas.
  • Suppression of glucagon secretion: The medication reduces glucagon release from pancreatic alpha cells, which in turn decreases hepatic glucose production and lowers fasting and postprandial glucose levels.
  • Delayed gastric emptying: Semaglutide slows the rate at which the stomach empties its contents into the duodenum, thereby blunting postprandial glucose excursions and promoting earlier satiety during meals.
  • Central appetite suppression: The drug acts on GLP-1 receptors in the hypothalamus and other brain regions involved in appetite regulation, leading to reduced hunger and decreased caloric intake.
  • Weight reduction: Through the combined effects of delayed gastric emptying and central appetite control, semaglutide consistently produces clinically meaningful weight loss, which is a critical therapeutic goal in prediabetes given the strong relationship between excess adiposity and insulin resistance.
  • Potential beta-cell preservation: Preclinical and clinical data suggest that GLP-1 receptor agonists may improve beta-cell function and slow the progressive decline in insulin secretory capacity that characterizes the transition from prediabetes to type 2 diabetes.

These mechanisms directly address the fundamental pathophysiologic defects that underlie prediabetes: insulin resistance, beta-cell dysfunction, and obesity. While metformin primarily reduces hepatic glucose production through AMP-kinase activation, Rybelsus offers a broader therapeutic profile that includes significant weight loss, which is a critical advantage given that visceral adiposity is a primary driver of insulin resistance and metabolic deterioration.

Clinical Evidence: Rybelsus in the Prediabetes Population

Although Rybelsus is not currently approved by the FDA specifically for the treatment of prediabetes, a growing body of evidence supports its potential utility in this population. The PIONEER clinical trial program, which evaluated oral semaglutide in patients with type 2 diabetes across multiple global studies, consistently demonstrated superior reductions in hemoglobin A1c and body weight compared with placebo and active comparators including sitagliptin, empagliflozin, and liraglutide. Importantly, post-hoc analyses of these trials have examined outcomes among participants who met the laboratory criteria for prediabetes at baseline.

In a pooled analysis of the PIONEER 1 through 5 and 8 trials, published in Diabetes Care, oral semaglutide significantly reduced the risk of progression from prediabetes to type 2 diabetes compared with placebo or active comparators. The hazard ratio was approximately 0.47, corresponding to a 53 percent relative risk reduction over the study duration. These findings are consistent with data from the SCALE trials of injectable liraglutide, which demonstrated a 79 percent risk reduction in individuals with prediabetes and obesity over a 3-year treatment period.

The STEP program evaluated injectable semaglutide at a dose of 2.4 mg weekly for weight management and found that participants lost an average of 15 percent of their baseline body weight. While Rybelsus is administered at lower daily doses (7 mg or 14 mg), it still produces a mean weight loss of 4 to 6 percent in patients with type 2 diabetes. This magnitude of weight loss is clinically meaningful, as the Diabetes Prevention Program showed that a 5 to 7 percent reduction in body weight lowers the risk of progressing to diabetes by 58 percent. For many prediabetic individuals, achieving this degree of weight loss through lifestyle modification alone is difficult, and Rybelsus may provide the pharmacologic leverage needed to reach and sustain this target.

Ongoing prospective trials are directly investigating the efficacy of Rybelsus for diabetes prevention. The PREDIMED trial, registered under ClinicalTrials.gov identifier NCT04777396, is randomizing adults with prediabetes and obesity to receive either oral semaglutide 14 mg daily or placebo, with the primary endpoint being progression to type 2 diabetes over a 3-year follow-up period. Results from this trial are anticipated within the next several years and are expected to provide definitive evidence that will inform future clinical practice guidelines.

Cardiovascular and Renal Protective Effects

Even in the absence of a formal indication for prediabetes, the cardiovascular benefits of semaglutide are highly relevant to this patient population, many of whom have concurrent cardiometabolic risk factors. The PIONEER 6 cardiovascular outcomes trial demonstrated that oral semaglutide reduced the risk of major adverse cardiovascular events by 21 percent in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk. The FLOW trial, which evaluated semaglutide on kidney outcomes, showed a 24 percent reduction in composite renal endpoints including progression to macroalbuminuria, doubling of serum creatinine, and kidney failure. For prediabetic patients who also have hypertension, dyslipidemia, or chronic kidney disease, these pleiotropic effects provide additional clinical value that extends beyond glucose lowering and weight reduction.

Comparative Effectiveness: Rybelsus Versus Current Prediabetes Interventions

The current standard of care for prediabetes, as outlined by the American Diabetes Association Standards of Medical Care in Diabetes, includes several evidence-based approaches:

  • Intensive lifestyle intervention: Structured programs that help patients achieve at least 7 percent weight loss and engage in 150 minutes of moderate-intensity physical activity per week. This remains the first-line recommendation for all patients with prediabetes.
  • Metformin: Recommended for patients under 60 years of age, those with a body mass index of 35 kg/m² or higher, or women with a history of gestational diabetes. Metformin reduces the risk of progression to diabetes by approximately 31 percent.
  • Other pharmacotherapy: Pioglitazone and acarbose have demonstrated efficacy in diabetes prevention but are limited by safety concerns including fluid retention, fracture risk, and potential bladder cancer risk with pioglitazone, and gastrointestinal intolerance with acarbose.

Rybelsus offers several potential advantages over metformin in the prediabetes context. While metformin typically reduces HbA1c by 1.0 to 1.2 percentage points and produces modest weight loss of 2 to 3 percent, Rybelsus achieves a greater reduction in HbA1c (up to 1.5 percentage points) and more substantial weight reduction (4 to 6 percent). Furthermore, the mechanism of action of semaglutide complements that of metformin, and combining the two agents may produce additive benefits, although this has not been specifically studied in prediabetes. Additionally, Rybelsus does not require dose adjustment for renal function, unlike metformin, which is contraindicated when the estimated glomerular filtration rate falls below 30 mL/min/1.73 m² and requires dose reduction when the eGFR is between 30 and 45 mL/min/1.73 m².

Another GLP-1 receptor agonist, liraglutide, is approved for weight management at a dose of 3.0 mg daily under the brand name Saxenda and has been shown to delay progression from prediabetes to diabetes. However, liraglutide requires daily subcutaneous injection, which is a barrier for many patients. The oral formulation of Rybelsus addresses this barrier, potentially improving adherence and broadening access to GLP-1 receptor agonist therapy. Cost remains a significant concern, as Rybelsus is a brand-name medication and insurance coverage varies widely. However, manufacturer patient assistance programs and copay savings cards can reduce out-of-pocket expenses for eligible individuals.

Safety Profile and Tolerability Considerations

Rybelsus is generally well-tolerated, but gastrointestinal side effects are common, particularly during dose initiation and escalation. The most frequently reported adverse events include nausea, vomiting, diarrhea, abdominal discomfort, and constipation. These effects are dose-dependent and tend to diminish over time as tolerance develops. To mitigate gastrointestinal symptoms, treatment is initiated at 3 mg daily for 30 days, then increased to 7 mg, and subsequently to 14 mg if clinically indicated and tolerated. Instructing patients to take the tablet with only a small amount of water and to avoid food for at least 30 minutes after dosing may help reduce nausea.

Rarer but serious risks associated with semaglutide include:

  • Acute pancreatitis: If persistent severe abdominal pain radiating to the back is suspected, semaglutide should be discontinued promptly and the patient evaluated. The medication is not recommended in patients with a history of pancreatitis.
  • Gallbladder disease: Semaglutide has been associated with an increased incidence of cholecystitis and cholelithiasis, likely related to weight loss and alterations in bile composition and gallbladder motility.
  • Thyroid C-cell tumors: Based on rodent studies, semaglutide carries a boxed warning regarding the risk of medullary thyroid carcinoma. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
  • Diabetic retinopathy complications: Rapid improvement in glycemic control with semaglutide has been associated with a transient worsening of preexisting diabetic retinopathy. This is less relevant in the prediabetes population, where retinopathy is typically absent.

For patients with prediabetes, the risk-benefit balance generally favors the use of Rybelsus in those with high-risk clinical features, including significant obesity, severe insulin resistance, metabolic syndrome, or concurrent cardiovascular or renal disease. A thorough discussion with a healthcare provider is essential, including consideration of the patient's comorbidities, treatment preferences, and ability to afford the medication over the long term.

Clinical Practice Implications: Identifying Optimal Candidates

Given the absence of an FDA-approved indication for prediabetes, clinicians who prescribe Rybelsus in this setting are doing so off-label. The decision to initiate therapy should be individualized and based on a careful assessment of the following factors:

  • High-risk prediabetes: Patients with HbA1c values in the upper range of prediabetes (6.0 to 6.4 percent), impaired fasting glucose of 110 mg/dL or higher, or impaired glucose tolerance confirmed by an oral glucose tolerance test are at particularly high risk for progression and may derive the greatest benefit.
  • Obesity: A body mass index of 30 kg/m² or higher, especially when accompanied by central obesity or features of metabolic syndrome, represents a strong indication for weight-focused pharmacotherapy.
  • Intolerance or contraindication to metformin: Patients who cannot tolerate metformin due to gastrointestinal side effects or who have renal function that precludes its use may be candidates for Rybelsus as an alternative first-line agent.
  • Inadequate weight loss with lifestyle intervention alone: Individuals who have not achieved the 7 percent weight loss target after a reasonable trial of structured lifestyle modification may benefit from pharmacologic augmentation.
  • Cardiometabolic comorbidity: Hypertension, dyslipidemia, established cardiovascular disease, or chronic kidney disease may benefit from the pleiotropic effects of semaglutide beyond glucose and weight control.

Regular monitoring is essential for patients on Rybelsus for prediabetes. HbA1c, fasting glucose, body weight, blood pressure, and renal function should be assessed every three to six months. The therapeutic goal is to achieve and maintain normoglycemia and clinically meaningful weight loss. If these targets are not met after 6 to 12 months of treatment, reassessment of the therapeutic strategy is warranted. Importantly, Rybelsus should never be used as a substitute for lifestyle modification but rather as an adjunct to amplify and sustain its effects.

Future Directions: Toward a New Prevention Paradigm

The role of Rybelsus in prediabetes management is likely to expand as additional clinical trial data become available. The completion of the PREDIMED trial and other ongoing studies may prompt the FDA to consider a formal indication for diabetes prevention. If approved, Rybelsus could join metformin as a first-line pharmacotherapy option for prediabetes, particularly for patients who prioritize weight loss as a therapeutic goal. Head-to-head comparisons between Rybelsus and metformin for prediabetes are not yet available, but the superiority of semaglutide in type 2 diabetes suggests that Rybelsus may become the more potent option for those who need it.

Combination strategies are also being explored. The feasibility of combining Rybelsus with metformin or with intensive lifestyle intervention is clinically logical, and prospective trials are needed to define the optimal sequencing and long-term outcomes of these approaches. The advent of oral semaglutide also raises the possibility of using lower doses solely for weight management or prevention, analogous to the higher-dose injectable formulation approved for obesity.

From a public health perspective, expanding access to GLP-1 receptor agonist therapy for the 96 million Americans with prediabetes could substantially reduce the incidence of type 2 diabetes and its downstream complications. However, cost and insurance barriers remain significant. Advocacy for coverage parity with metformin and lifestyle programs, as well as continued development of lower-cost generic formulations, will be essential to realize the full potential of this medication at the population level.

Conclusion

Rybelsus represents a powerful new tool for addressing prediabetes. Its ability to lower blood glucose, induce clinically meaningful weight loss, and provide cardiovascular and renal protective effects positions it as a promising adjunct to lifestyle intervention. While not yet formally approved for prediabetes, the existing evidence from post-hoc analyses, extrapolation from type 2 diabetes trials, and mechanistic plausibility strongly supports its potential to delay or prevent progression to overt diabetes. As ongoing research continues to define its role, Rybelsus may transform the preventive pharmacotherapy landscape and offer new hope to the millions of individuals at risk. Clinicians and patients should carefully weigh the benefits against the costs and potential side effects and integrate this medication into a comprehensive, patient-centered management plan that prioritizes sustainable behavior change and long-term metabolic health.

References and further reading: American Diabetes Association Standards of Medical Care in Diabetes, Diabetes Prevention Program Research Group, PIONEER trial publications in Diabetes Care, and the National Institute of Diabetes and Digestive and Kidney Diseases.